This study is testing a new medicine called Vilobelimab for a skin condition named ulcerative pyoderma gangrenosum (PG). PG is a rare disease that causes painful skin ulcers. The study is double-blind, meaning neither the patients nor the doctors will know who is getting the real medicine or a placebo (a fake treatment). This helps ensure the results are fair. The trial is adaptive, which means it can change based on how things are going.

To join the study, you need to be 18 or older, have a confirmed diagnosis of PG, and at least one ulcer that meets specific size requirements. You cannot join if your ulcer is too large, in transplanted skin, or if you had certain treatments recently. If you have been on Vilobelimab before, you can't participate either.

• Participation involves regular visits to the study site.
• There may be some risks involved, like side effects from the medication.
• Participants may receive compensation for their time and travel.

This study offers a chance to try a potential new treatment for PG and help advance medical research. Always discuss with your doctor before joining any clinical trial.